Interactions between SIRT5 and SARS-CoV-2 Nsp14 protein BuckInstitute SARSCoV2 COVID19 Coronavirus SIRT5 Nsp14 Protein
By Bhavana KunkalikarSep 14 2022Reviewed by Aimee Molineux In a recent study published in the PLOS Pathogens journal, researchers investigated the interactions between sirtuin 5 and severe acute respiratory syndrome coronavirus 2 nonstructural protein protein.
About the study In the present study, researchers assessed the characteristics of SARS-CoV-2 Nsp14 and SIRT5 interaction and SIRT5's function in SARS-CoV-2 infection. The study also determined whether Nsp10 and SIRT5 were components of separate complexes or whether they interacted as well. Using clustered regularly interspaced short palindromic repeats interference in HEK-293T cells, the team created a SIRT5 knockdown cell line to remove endogenous expression of SIRT5. A single guide ribonucleic acid was chosen after testing several others throughout the investigation.
Strep affinity purification confirmed SIRT5 and Nsp10 interactions with Nsp14. However, using Flag-IP to remove Nsp10 revealed that only Nsp14 co-purified with Nsp10. This demonstrated that Nsp10 and SIRT5 did not interact. The team also hypothesized that Nsp10 and SIRT5 were in direct competition for Nsp14 binding because the SIRT5 signal after Strep-AP appeared to be diminished in the presence of Nsp10.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Portable SARS-CoV-2 Sensor Using Freestanding Laser-Induced GrapheneAn article published in the journal ACS Applied Materials and Interfaces discussed the fabrication of highly sensitive sensors, freestanding laser-induced graphene (FLIG) flakes to reliably detect SARS-CoV-2.
Read more »
Intranasal administration of liposomes displaying SARS-CoV-2 antigen induces mucosal immunityIntranasal administration of liposomes displaying SARS-CoV-2 antigen induces mucosal immunity MDPIOpenAccess UBuffalo SARSCoV2 COVID19 Coronavirus MucosalImmunity
Read more »
Efficacy and safety of monoclonal antibodies against SARS-CoV-2 during pregnancyIn an article published in the journal Expert Opinion on Drug Safety, scientists have described the safety and efficacy profiles of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibodies in pregnant women with coronavirus disease 2019 (COVID-19).
Read more »
Parenteral-prime mucosal boost an effective strategy to protect against SARS-CoV-2In a recent study published in the journal eBioMedicine, researchers in Denmark and Sweden administered a cationic liposome-adjuvanted severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein subunit vaccine as a subcutaneous (s.c.) prime-intranasal (i.n.) boost strategy to elicit mucosal immune responses among SARS-CoV-2-infected Syrian hamsters.
Read more »
Small molecule inhibitor found to be effective against SARS-CoV-2 variantsIn a new study, researchers developed RK-33, a small molecule inhibitor of DDX3, and evaluated its efficacy against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs).
Read more »
BNT162b2 SARS-CoV-2 vaccinations found to reduce incidence of long COVID symptomsResearchers assessed the association between Pfizer-BioNTech’s SARS-CoV-2 BNT162b2 messenger ribonucleic acid (mRNA) vaccination and the incidence of post-COVID-19 symptoms among Israeli adults.
Read more »